Skip to main content

Table 2 Baseline details of the 865 ICSI cycles.

From: A comparison of menotropin, highly-purified menotropin and follitropin alfa in cycles of intracytoplasmic sperm injection

  hMG
(n = 299)
HP-hMG
(n = 330)
r-hFSH
(n = 236)
p value
Mean age, years (± SD) 32.5 (± 5.3)a 34.0 (± 4.7)b 34.3 (± 4.8)c < 0.001
(a vs b, c)
   ≤35 years, n (%) 213 (71.2)a 198 (60.0)b 142 (60.2)c 0.005
(a vs b, c)
   >35 years, n (%) 86 (28.8)a 132 (40.0)b 94 (39.8)c 0.005
(a vs b, c)
Indication, n (%)     
   Male factor only 111 (37.1) 99 (30.0) 76 (32.2) 0.27
   Mixed factor* 142 (47.5) 156 (47.3) 129 (54.7) 0.19
   Female factor 46 (15.4) 75 (22.7) 31 (13.1) 0.33
Treatment cycle, n (%)     
   1st cycle 195 (65.3) 192 (58.1) 145 (61.4) 0.49
   2nd cycle 80 (26.7) 86 (26.0) 60 (25.4) 0.83
   ≥3rd cycle 24 (8.0) 52 (15.9) 31 (13.2) 0.34
Mean baseline FSH, IU/L (± SD) 6.3 (± 3.2) 6.7 (± 3.7) 6.5 (± 2.8) 0.33
   ≤35 years 6.0 (± 2.8) 6.5 (± 3.1) 6.1 (± 3.0) 0.23
   >35 years 7.2 (± 3.9) 7.2 (± 4.4) 7.3 (± 4.7) 0.69
Mean baseline LH, IU/L (± SD) 4.9 (± 4.1) 5.4 (± 4.4) 5.2 (± 3.7) 0.23
   ≤35 years 5.2 (± 4.4) 5.2 (± 4.1) 5.1 (± 3.9) 0.63
   >35 years 4.2 (± 3.0)a 5.8 (± 4.8)b 4.3 (± 3.9)c 0.004
(b vs a, c)
  1. Distribution by menotropin (hMG), highly-purified menotropin (HP-hMG) or follitropin alfa (r-hFSH), after pituitary down-regulation, in relation to the age, indication, baseline FSH and LH levels, and total number of treated cycles.
  2. *Mixed factor: male + female.
  3. FSH, follicle stimulating hormone; hMG, human menopausal gonadotropin; HP-hMG, highly-purified hMG; ICSI, intracytoplasmic sperm injection; LH, luteinizing hormone; r-hFSH, recombinant human FSH; SD, standard deviation.